This information is from August 18, 2021 and may be changed in the future with updates in the science.
COVID-19 Vaccines: On Friday, ACIP recommended that people who are moderately to severely immunocompromised could receive a third dose of mRNA COVID-19 vaccine.
- Evidence indicates that people with severe immunocompromise don’t always build the same level of immunity after two doses of mRNA vaccination as people without immunocompromise, and may benefit from an additional dose of COVID-19 vaccine.
- The third dose should be administered at least four weeks after the second dose of the same mRNA vaccine.
- Healthcare providers should talk with patients who are immunocompromised about whether a third dose is appropriate for them. Patients included in ACIP’s recommendations can get a third dose of mRNA vaccine. See FAQs under the recommendations for more information.
- DPH encourages all providers to reach out to patients who may meet the criteria for an additional dose of a COVID-19 vaccine to support and encourage them to get the additional dose.
- FDA has amended both the Pfizer-BioNTech EUA and the Moderna EUA